Asset Details
Do you wish to reserve the book?
Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen
Do you wish to request the book?
Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen
2018
Overview
Objective. To measure spermatogenesis abnormalities in transwomen at the time of sex reassignment surgery (SRS) and to analyze the association between hormonal therapy duration and infertility severity. Design. Retrospective study. Setting. University hospital. Patients. One-hundred seventy-three transwomen who underwent SRS from January 2000 to December 2015. Interventions. All orchidectomy specimens were retrospectively reviewed and classified. History of hormonal therapy duration was retrieved from medical records. Main Outcome Measures. Histological examinations of orchidectomy specimens were performed to assess spermatogenesis. Results. One-hundred seventy-three orchidectomy specimens were evaluated. Histological examinations showed maturation arrest in 36.4%, hypospermatogenesis in 26%, Sertoli cell-only syndrome in 20.2%, normal spermatogenesis in 11%, and seminiferous tubule hyalinization in 6.4% of the specimens. Spermatogenesis abnormality severity was not associated with the total therapy duration (P=0.81) or patient age at the time of surgery (P=0.88). Testicular volumes and sizes were associated with spermatogenesis abnormality severity (P=0.001 and P=0.026, right testicle and left testicle, resp.). Conclusion(s). Feminizing hormonal treatment leads to reductions in testicular germ cell levels. All transwomen should be warned about this consequence, and gamete preservation should be offered before starting hormonal treatment.
Publisher
Hindawi Publishing Corporation,Hindawi,John Wiley & Sons, Inc
Subject
/ Adult
/ Androgen Antagonists - adverse effects
/ Androgen Antagonists - therapeutic use
/ Hormones
/ Humans
/ Infertility, Male - chemically induced
/ Male
/ Patients
/ Sex Reassignment Procedures - adverse effects
/ Sex Reassignment Procedures - methods
/ Sperm
/ Spermatogenesis - drug effects
/ Surgery
/ Testes
/ Therapy
/ Urology
